PATENT CLAIM ANALYSIS

Application Number: 15780462
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "210180"]

Abstract:
Use of a GPR119 agonist in the prevention or treatment of hypoglycemia is disclosed, addition, pharmaceutical compositions and combinations of a GPR1 19 agonist with insulin, insulin analog, insulin secretagogue or or other drug(s) that reduces plasma glucose levels to below 70 mg/dL described herein.

Claim (Index 5):
The method of  claim 4  wherein the insulin or insulin analog is selected from human insulin, NPH insulin, insulin lispro, insulin aspart, insulin glulisine, insulin detemir, insulin glargine, insulin degludec, insulin peglispro, insulin known as NN1436 (LA1287), or insulin known as NN1218.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 93.0
- Lexical Diversity: 1.2619
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12610639', '12610682', '12610877', '11927535', '11927621']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7839763429863269
- 35 USC 102 Novelty (BERT): 0.519502548114439
- Combined Prediction Score: 0.7575289634991381
- Mean Citation Score: 282.4480779999999
- Max Citation Score: 288.3848
- Similarity Product: 194.44675362730027

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test